Systematic Review with Meta-Analysis: Fecal Calprotectin as a Surrogate Marker for Predicting Relapse in Adults with Ulcerative Colitis

Table 2

Assessment of diagnostic accuracy and heterogeneity in subgroup analysis.

Category	Number of studies	Sensitivity	Specificity	PLR	NLR	DOR	(%) of DOR
Total	14	0.75 (0.70–0.79)	0.77 (0.74–0.80)	3.45 (2.31–5.14)	0.37 (0.28–0.49)	10.54 (6.16–18.02)	57.0
Number of patients
≥80	6	0.78 (0.72-0.83)	0.75 (0.71-0.79)	3.39 (1.77-6.51)	0.32 (0.23-0.43)	11.18 (4.96-25.19)	72.5
<80	8	0.68 (0.59-0.76)	0.81 (0.76-0.85)	3.38 (2.10-5.43)	0.44 (0.30-0.63)	9.60 (4.57-20.15)	39.5
Mean age
≥40	10	0.73 (0.67-0.79)	0.75 (0.71-0.79)	3.34 (2.00-5.58)	0.40 (0.30-0.53)	9.61 (4.75-19.47)	62.3
<40	4	0.77 (0.68-0.85)	0.81 (0.76-0.86)	3.92 (2.96-5.20)	0.30 (0.15-0.62)	13.44 (6.31-28.60)	34.9
Male ratio
≥50%	10	0.75 (0.70-0.80)	0.75 (0.72-0.79)	3.71 (1.97-5.10)	0.37 (0.26-0.52)	9.98 (5.16-19.32)	67.7
<50%	4	0.70 (0.53-0.84)	0.84 (0.78-0.89)	4.31 (2.38-7.80)	0.39 (0.24-0.62)	12.49 (5.31-29.37)	0
FC assay
Bühlmann	4	0.75 (0.65-0.83)	0.87 (0.80-0.91)	5.07 (3.32-7.75)	0.34 (0.16-0.72)	15.35 (5.28-44.61)	44.8
Not Bühlmann	10	0.74 (0.68-0.80)	0.75 (0.71-0.78)	3.05 (1.98-4.69)	0.38 (0.28-0.52)	9.34 (5.06-17.24)	58.0
Cutoff value
≥150 μg/g	9	0.71 (0.65-0.78)	0.86 (0.82-0.89)	4.42 (3.00-6.53)	0.38 (0.26-0.55)	14.06 (7.17-27.58)	49.9
<150 μg/g	5	0.79 (0.71-0.85)	0.64 (0.58-0.69)	2.19 (1.32-3.64)	0.36 (0.25-0.50)	6.72 (2.95-15.47)	59.8
Follow-up time
≥1 y	12	0.73 (0.68-0.78)	0.81 (0.78-0.84)	3.66 (2.52-5.31)	0.38 (0.28-0.50)	11.18 (6.32-19.78)	59.8
<1 y	2	0.89 (0.72-0.98)	0.44 (0.33-0.57)	2.20 (0.66-7.28)	0.31 (0.11-0.88)	7.01 (0.92-53.25)	41.0